Go back to the Europarl portal

Choisissez la langue de votre document :

  • bg - български
  • es - español
  • cs - čeština
  • da - dansk
  • de - Deutsch
  • et - eesti keel
  • el - ελληνικά
  • en - English (Selected)
  • fr - français
  • ga - Gaeilge
  • hr - hrvatski
  • it - italiano
  • lv - latviešu valoda
  • lt - lietuvių kalba
  • hu - magyar
  • mt - Malti
  • nl - Nederlands
  • pl - polski
  • pt - português
  • ro - română
  • sk - slovenčina
  • sl - slovenščina
  • fi - suomi
  • sv - svenska
Parliamentary questions
PDF 40kWORD 17k
25 March 2019
P-001476-19
Question for written answer P-001476-19
to the Commission
Rule 130
Kathleen Van Brempt (S&D)

 Subject:  Orphan medicinal products — follow-up question

With reference to the reply to Question P-000817/2019 (22 March 2019), can the Commission answer the following additional questions?

1. In the case of the orphan medicinal product CDCA discussed (on which the Italian pharmaceutical company Leadiant Biosciences holds a monopoly), has the Commission already launched a competition inquiry pursuant to Article 102 TFEU?

2. If the Commission has not yet launched such an inquiry, does it intend to do so?

3. If not, why not?

Original language of question: NL 
Last updated: 3 April 2019Legal notice